Combined anti-microtubule therapy

A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer

S. E. Soule, Kathy Miller, R. Ansari, F. Fata, J. McClean, R. Zon, P. Porcu, G. Sledge, Lawrence Einhorn

Research output: Contribution to journalArticle

Abstract

Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data demonstrate synergism with this combination. This phase II study evaluated the response rate and toxicity of this combination in patients with metastatic breast cancer (MBC). Eligible patients had received no more than one non-taxane chemotherapy regimen for metastatic disease; adjuvant taxane therapy was allowed if completed one year prior to enrollment. Patients were treated with docetaxel 35 mg/m2 d2 and estramustine phosphate 280 mg po TID d1-d3, weekly for 3 of 4 weeks. Patients were not treated with prophylactic anticoagulation. Thirty-six patients were enrolled between August 1999 and March 2001. Three patients discontinued therapy prior to disease assessment for reasons other than disease progression or dose limiting toxicity: one patient discontinued due to treatment-related toxicity. Median patient age was 54.8 years; the mean KPS was 90%. Six patients had received adjuvant taxane therapy and two patients had been treated with prior chemotherapy for MBC. Toxicity data is available in all patients. Myelosuppression was limited, with only two episodes of grade 4 neutropenia and no neutropenic fevers. One patient had grade 3 thrombocytopenia. Thromboembolic events occured in 11 % of patients, including 3 episodes of deep venous thrombosis and one treatment-related death due to a pulmonary embolus. Three patients had grade 3 fatigue or myalgias; two patients had grade 3 diarrhea and two patients had grade 3 nausea and vomiting. One patient was removed from the study due to grade 4 dyspnea. Responses were seen in 12 patients (40%) with confirmed partial remissions and two patients (7%) with complete remission; 10 patients (33%) had progressive disease; six (20%) had stable disease for ≥2 months; evaluation is not yet available in one patient. This combination has modest activity in patients with metastatic breast cancer hut has unacceptable thromboembolic toxicity.

Original languageEnglish
Pages (from-to)273
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001

Fingerprint

docetaxel
Estramustine
Microtubules
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combined anti-microtubule therapy : A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. / Soule, S. E.; Miller, Kathy; Ansari, R.; Fata, F.; McClean, J.; Zon, R.; Porcu, P.; Sledge, G.; Einhorn, Lawrence.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 273.

Research output: Contribution to journalArticle

@article{bf7bdbf3c070494f9ef80e78d37b83a0,
title = "Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer",
abstract = "Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data demonstrate synergism with this combination. This phase II study evaluated the response rate and toxicity of this combination in patients with metastatic breast cancer (MBC). Eligible patients had received no more than one non-taxane chemotherapy regimen for metastatic disease; adjuvant taxane therapy was allowed if completed one year prior to enrollment. Patients were treated with docetaxel 35 mg/m2 d2 and estramustine phosphate 280 mg po TID d1-d3, weekly for 3 of 4 weeks. Patients were not treated with prophylactic anticoagulation. Thirty-six patients were enrolled between August 1999 and March 2001. Three patients discontinued therapy prior to disease assessment for reasons other than disease progression or dose limiting toxicity: one patient discontinued due to treatment-related toxicity. Median patient age was 54.8 years; the mean KPS was 90{\%}. Six patients had received adjuvant taxane therapy and two patients had been treated with prior chemotherapy for MBC. Toxicity data is available in all patients. Myelosuppression was limited, with only two episodes of grade 4 neutropenia and no neutropenic fevers. One patient had grade 3 thrombocytopenia. Thromboembolic events occured in 11 {\%} of patients, including 3 episodes of deep venous thrombosis and one treatment-related death due to a pulmonary embolus. Three patients had grade 3 fatigue or myalgias; two patients had grade 3 diarrhea and two patients had grade 3 nausea and vomiting. One patient was removed from the study due to grade 4 dyspnea. Responses were seen in 12 patients (40{\%}) with confirmed partial remissions and two patients (7{\%}) with complete remission; 10 patients (33{\%}) had progressive disease; six (20{\%}) had stable disease for ≥2 months; evaluation is not yet available in one patient. This combination has modest activity in patients with metastatic breast cancer hut has unacceptable thromboembolic toxicity.",
author = "Soule, {S. E.} and Kathy Miller and R. Ansari and F. Fata and J. McClean and R. Zon and P. Porcu and G. Sledge and Lawrence Einhorn",
year = "2001",
language = "English",
volume = "69",
pages = "273",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Combined anti-microtubule therapy

T2 - A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer

AU - Soule, S. E.

AU - Miller, Kathy

AU - Ansari, R.

AU - Fata, F.

AU - McClean, J.

AU - Zon, R.

AU - Porcu, P.

AU - Sledge, G.

AU - Einhorn, Lawrence

PY - 2001

Y1 - 2001

N2 - Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data demonstrate synergism with this combination. This phase II study evaluated the response rate and toxicity of this combination in patients with metastatic breast cancer (MBC). Eligible patients had received no more than one non-taxane chemotherapy regimen for metastatic disease; adjuvant taxane therapy was allowed if completed one year prior to enrollment. Patients were treated with docetaxel 35 mg/m2 d2 and estramustine phosphate 280 mg po TID d1-d3, weekly for 3 of 4 weeks. Patients were not treated with prophylactic anticoagulation. Thirty-six patients were enrolled between August 1999 and March 2001. Three patients discontinued therapy prior to disease assessment for reasons other than disease progression or dose limiting toxicity: one patient discontinued due to treatment-related toxicity. Median patient age was 54.8 years; the mean KPS was 90%. Six patients had received adjuvant taxane therapy and two patients had been treated with prior chemotherapy for MBC. Toxicity data is available in all patients. Myelosuppression was limited, with only two episodes of grade 4 neutropenia and no neutropenic fevers. One patient had grade 3 thrombocytopenia. Thromboembolic events occured in 11 % of patients, including 3 episodes of deep venous thrombosis and one treatment-related death due to a pulmonary embolus. Three patients had grade 3 fatigue or myalgias; two patients had grade 3 diarrhea and two patients had grade 3 nausea and vomiting. One patient was removed from the study due to grade 4 dyspnea. Responses were seen in 12 patients (40%) with confirmed partial remissions and two patients (7%) with complete remission; 10 patients (33%) had progressive disease; six (20%) had stable disease for ≥2 months; evaluation is not yet available in one patient. This combination has modest activity in patients with metastatic breast cancer hut has unacceptable thromboembolic toxicity.

AB - Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data demonstrate synergism with this combination. This phase II study evaluated the response rate and toxicity of this combination in patients with metastatic breast cancer (MBC). Eligible patients had received no more than one non-taxane chemotherapy regimen for metastatic disease; adjuvant taxane therapy was allowed if completed one year prior to enrollment. Patients were treated with docetaxel 35 mg/m2 d2 and estramustine phosphate 280 mg po TID d1-d3, weekly for 3 of 4 weeks. Patients were not treated with prophylactic anticoagulation. Thirty-six patients were enrolled between August 1999 and March 2001. Three patients discontinued therapy prior to disease assessment for reasons other than disease progression or dose limiting toxicity: one patient discontinued due to treatment-related toxicity. Median patient age was 54.8 years; the mean KPS was 90%. Six patients had received adjuvant taxane therapy and two patients had been treated with prior chemotherapy for MBC. Toxicity data is available in all patients. Myelosuppression was limited, with only two episodes of grade 4 neutropenia and no neutropenic fevers. One patient had grade 3 thrombocytopenia. Thromboembolic events occured in 11 % of patients, including 3 episodes of deep venous thrombosis and one treatment-related death due to a pulmonary embolus. Three patients had grade 3 fatigue or myalgias; two patients had grade 3 diarrhea and two patients had grade 3 nausea and vomiting. One patient was removed from the study due to grade 4 dyspnea. Responses were seen in 12 patients (40%) with confirmed partial remissions and two patients (7%) with complete remission; 10 patients (33%) had progressive disease; six (20%) had stable disease for ≥2 months; evaluation is not yet available in one patient. This combination has modest activity in patients with metastatic breast cancer hut has unacceptable thromboembolic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=33749100320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749100320&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 273

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -